Skip to main content
Journal cover image

Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.

Publication ,  Journal Article
Lincoff, AM; LeNarz, LA; Despotis, GJ; Smith, PK; Booth, JE; Raymond, RE; Sapp, SK; Cabot, CF; Tcheng, JE; Califf, RM; Effron, MB; Topol, EJ
Published in: Ann Thorac Surg
August 2000

BACKGROUND: Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk should emergency coronary surgical procedures be required. METHODS: Outcomes were assessed among 85 patients who required coronary artery bypass grafting operations after coronary intervention in two randomized placebo-controlled trials of abciximab. Comparisons were made between patients in the pooled placebo and abciximab groups. RESULTS: The incidence of coronary surgical procedures was 2.17% and 1.28% among patients randomized to placebo and abciximab, respectively (p = 0.021). Platelet transfusions were administered to 32% and 52% of patients in the placebo and abciximab groups, respectively (p = 0.059). Rates of major blood loss were 79% and 88% in the placebo and abciximab groups, respectively (p = 0.27); transfusions of packed red blood cells or whole blood were administered in 74% and 80% of patients, respectively (p = 0.53). Surgical reexploration for bleeding was required in 3% and 12% of patients, respectively. Death and myocardial infarction tended to occur less frequently among patients who had received abciximab. CONCLUSIONS: Urgent coronary artery bypass grafting operations can be performed without an incremental increase in major hemorrhagic risk among patients on abciximab therapy.

Duke Scholars

Published In

Ann Thorac Surg

DOI

ISSN

0003-4975

Publication Date

August 2000

Volume

70

Issue

2

Start / End Page

516 / 526

Location

Netherlands

Related Subject Headings

  • Stents
  • Risk Factors
  • Respiratory System
  • Randomized Controlled Trials as Topic
  • Platelet Aggregation Inhibitors
  • Multicenter Studies as Topic
  • Immunoglobulin Fab Fragments
  • Humans
  • Emergency Treatment
  • Coronary Artery Bypass
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lincoff, A. M., LeNarz, L. A., Despotis, G. J., Smith, P. K., Booth, J. E., Raymond, R. E., … Topol, E. J. (2000). Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. Ann Thorac Surg, 70(2), 516–526. https://doi.org/10.1016/s0003-4975(00)01343-6
Lincoff, A. M., L. A. LeNarz, G. J. Despotis, P. K. Smith, J. E. Booth, R. E. Raymond, S. K. Sapp, et al. “Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.Ann Thorac Surg 70, no. 2 (August 2000): 516–26. https://doi.org/10.1016/s0003-4975(00)01343-6.
Lincoff AM, LeNarz LA, Despotis GJ, Smith PK, Booth JE, Raymond RE, Sapp SK, Cabot CF, Tcheng JE, Califf RM, Effron MB, Topol EJ. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. Ann Thorac Surg. 2000 Aug;70(2):516–526.
Journal cover image

Published In

Ann Thorac Surg

DOI

ISSN

0003-4975

Publication Date

August 2000

Volume

70

Issue

2

Start / End Page

516 / 526

Location

Netherlands

Related Subject Headings

  • Stents
  • Risk Factors
  • Respiratory System
  • Randomized Controlled Trials as Topic
  • Platelet Aggregation Inhibitors
  • Multicenter Studies as Topic
  • Immunoglobulin Fab Fragments
  • Humans
  • Emergency Treatment
  • Coronary Artery Bypass